A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Adverse reactions
- Acronyms MIMAS
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 11 Jun 2018 Planned End Date changed from 14 Jan 2020 to 14 Nov 2019.
- 11 Jun 2018 Planned primary completion date changed from 14 Jan 2020 to 14 Nov 2019.